Back to top

Ligand price target raised to $335 from $275 at Benchmark

Benchmark analyst Robert Wasserman raised the firm’s price target on Ligand (LGND) to $335 from $275 and keeps a Buy rating on the shares after the...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ligand Pharmaceuticals Incorporated (LGND)